Mikkel O. Andersen, MD, of Middelfart Hospital in Denmark, reported results from the IVANOS study investigating Cerapedics' i-FACTOR Peptide Enhanced Bone Graft.
The study involved 98 patients aged 60 or older who suffered from lumbar spinal stenosis or concomitant degenerative olisthesis. The patients underwent non-instrumented lumbar posterolateral spine surgery with either i-FACTOR Peptide Enhanced Bone Graft or allograft.
Here are three insights.
1. At one-year postoperative follow-up, researchers found a 50 percent fusion rate using i-FACTOR versus a 20 percent fusion rate using allograft.
2. Those patients with one-level concomitant degenerative olisthesis accomplished estimated fusion rates of 40 percent with i-FACTOR compared to 21 percent with allograft.
3. Two-level concomitant degenerative olisthesis patients saw estimated fusion rates of 63 percent with i-FACTOR compared to 18 percent with allograft.
"These data indicate that i-FACTOR Peptide Enhanced Bone Graft offers significant potential benefits in fusion rates compared to allograft," said Dr. Andersen.